Detecting the Deadliest Cancers at Early Stages with Blood Samples

Jo Bhakdi, Founder and CEO of Quantgene

Detecting the Deadliest Cancers at Early Stages with Blood Samples

Today, we are privileged to feature the outstanding Jo Bhakdi, Founder and CEO of Quantgene. Jo discusses how his company is building the most advanced genomics technology that can detect cancer and other diseases earlier, while they are easier to treat. He talks about the genesis of the Quantgene, the benefits of merging genomic sequencing with AI, Serenity System and it’s amazing ability to detect diseases, the challenges they faced, and many more.

Jo and his team are building the future of medicine, which is so exciting. Learn more about Quantgene and how it can impact healthcare in this podcast episode.

Detecting the Deadliest Cancers at Early Stages with Blood Samples

About Jo Bhakdi

Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine.

Prior to Quantgene, Jo founded i2X, an investment framework that composes low-risk Venture Capital portfolios across large numbers of technology startups. The i2X platform laid important foundations for advanced analytics in both financial and biotechnology applications, such as the Quantgene machine learning platform.

Bhakdi holds a Masters in Economics and Psychology from Tubingen University, one of Germany’s leading academic institutions, with a focus on financial theory and statistics. He kicked off his career at WPP and Omnicom, where he held Strategy and Executive Director positions.

Beyond his focus on technology and the future of medicine, Bhakdi is dedicated to bringing together the best and brightest and transforming them into pioneers, pushing the boundaries of health, life, and innovation for all.

Things You’ll Learn

  • Get rid of the dependencies and the innovation cycles become much shorter.
  • Having a holistic perspective ties your innovation efforts so patients get the highest value.
  • It’s just intuitively pretty clear that if you do early detection effectively and predictive analytics genetics and take the right measures for protecting health, that this is probably good for your cost curve in the long run or maybe even in the short run.
  • It’s good to invest in preventative care because you’re driving down costs.
  • If you’re doing something new, listen to everyone, believe no one.
  • It’s those that have the strongest vision and mission that stay with it, that makes it.
  • Serenity is a system of preventative medicine that is tailored to your genes.
  • The cost of genetic sequencing against the use of big-data analytics and AI has decreased.
  • Serenity’s mission is to democratize genomics-based medicine.



Email: JB@quantgene.com

Website: https://www.quantgene.com/


Serenity’s webpage: https://chooseserenity.com/

LinkedIn: https://www.linkedin.com/in/jo-bhakdi-5048811/